Business
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutionsJERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247
About this update from Scynexis, Inc.
[{"type":"image","alt":"Scynexis","displaySize":"","headline":null,"caption":"Scynexis","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/6e640369b5a4d26f13c5b336ff4b47c4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zxf0PtiEj_fhfiPgUpXZlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6e640369b5a4d26f13c5b336ff4b47c4","width":300,"height":68}},"lazy":false},{"type":"text","content":"This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutions","length":163,"tagName":"p"},{"type":"text","content":"JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), which is taking place from January 28 to 30, 2026, in Las Vegas, Nevada.","length":511,"tagName":"p"},{"type":"text","content":"“We are pleased to participate in this important inaugural multidisciplinary meeting focused on addressing the significant threat of antimicrobial resistance,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “The potent in vitro and in vivo antifungal activity of our second-generation fungerp, SCY-247, together with the favorable safety profile and pharmacokinetics observed in clinical investigations to date, position this novel agent as a potentially critical weapon in the fight against deadly fungal infections, including those resistant to existing antifungal therapies. We look forward to sharing our development progress with the scientific community at IMARI, an especially timely conference given the growing recognition of the serious impact to human health posed by antifungal resistance.”","length":846,"tagName":"p"},{"type":"text","content":"An oral presentation of SCY-247 highlighting its antifungal activity against resistant fungi, will be included in the Plenary session “New Antimicrobial Agents in The Pipeline:...